ISA Workshop – Amyloidosis from Bench to Bedside and Back Again
Il Collegio Fondazione Ghislieri
October 13-14, 2025
The International Society of Amyloidosis (ISA) organized the ISA Workshop “Amyloidosis from Bench to Bedside and Back Again” at the Collegio Fondazione Ghislieri in Pavia, Italy, on October 13 and 14, 2025.
This focused workshop brought together leading experts, researchers, and clinicians in the field of amyloidosis to discuss cutting-edge advancements in diagnostics, treatment response assessment, screening approaches, and drug development.
The workshop explored novel approaches to assessing treatment response in AL and ATTR amyloidosis, focusing on measurable residual disease (MRD), advanced imaging techniques, biomarkers, and patient-reported outcomes to enhance clinical decision-making. It also highlighted advancements in screening and early diagnosis, examining genetic predisposition, artificial intelligence applications, and novel biomarkers aimed at improving early detection and patient outcomes.
A key focus was on drug development and therapeutic innovations, particularly AI-driven drug repurposing, targeted therapies, and emerging research models, which aimed to accelerate the development of effective treatments. The event also emphasized global collaboration and registry initiatives, addressing international standards for research and the importance of cross-border sample sharing to foster innovation and improve amyloidosis management worldwide.
Sponsors
The Workshop: Amyloidosis from Bench to Bedside and Back Again that took place on 13–14 October 2025 in Pavia, Italy, was independently organized and delivered by the International Society of Amyloidosis (ISA). ISA retained full control over the Programme’s content, speaker selection, and scientific direction. This workshop reflected ISA’s commitment to advancing translational research, fostering global collaboration, and promoting innovation in the field of amyloidosis. ISA gratefully acknowledges funding from AstraZeneca, Bayer, Bridgebio, Alnylam and Protego Bio for this workshop. AstraZeneca has provided a sponsorship grant towards this independent Programme. These contributions did not influence the content, structure, or outcomes of the event.